key: cord-1011918-342sff0m
authors: boudihi, Abdelaziz; Derar, Charmake; Mazouzi, Mosaab; ismaili, Nabila; el ouafi, Noha
title: Association of pulmonary embolism and acute coronary syndrome during COVID-19 infection: Case report and a brief review
date: 2021-12-04
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2021.103152
sha: f19d92c0bd8aaf9c8bb428a879691d81cb890a91
doc_id: 1011918
cord_uid: 342sff0m

INTRODUCTION AND IMPORTANCE: COVID 19 infection is considered a potentially serious disease since it is responsible for important respiratory and cardiovascular complications with a high morbid-mortality. CASE PRESENTATION: We report the case of a 54-year-old diabetic patient with hypertension who was admitted for heart failure with a reduced LVEF of 23% triggered by a pulmonary embolism and an acute coronary syndrome in the context of COVID-19 infection. CLINICAL DISCUSSION: Indeed, these complications may be secondary to a prothrombotic and hypercoagulable state as well as endothelial dysfunction caused by the vascular and systemic inflammation and cytokine storm induced by SARS-CoV-2. Although the clinical polymorphism of COVID 19 infection is recognized, the association of myocardial ischemia with pulmonary embolism is uncommon and of adverse prognosis. This justifies a rapid and adapted multidisciplinary management. CONCLUSION: In the absence of contraindication, thromboprohylaxis should be initiated for all hospitalized patients with COVID-19 to minimize the risk of thromboembolic complications.

Since its emergence in China, the increased risk of thrombosis, either venous or arterial, associated with COVID19 infection has been demonstrated by several studies. Because of their high incidence, especially in cases of severe disease, and their considerable mortality rate [1] , these complications remain a major medical challenge, both in terms of diagnosis and prognosis, despite wellmanaged preventive anticoagulation. Here we will describe the case of a patient with COVID-19 infection concomitantly complicated by pulmonary embolism and acute coronary syndrome. From this case we want to show one of the serious situations that can occur during this pandemic such as the coincidence between an acute coronary syndrome and a pulmonary embolism and the therapeutic guidelines that can be followed.

We report the case of a 54-year-old patient, with no previous pathological history, who initially consulted for a symptomatology consisting of dyspnea, asthenia, and myalgia associated with an lower limbs oedema since two months.

On admission, the patient was in congestive heart failure: dyspnea, blood pressure (BP) was 140/70 mmHg, heart rate (HR) was 110 bpm, spontaneous SpO2 was 88%, and he had basithoracic crepitus rales and lower extremity edema. In addition to the cytokine storm and endothelial injury [3, 4] , several factors are responsible for the hypercoagulable state frequently associated with covid 19 infection including the sepsis state, inflammation, hypoxia, immobilization and diffuse intravascular coagulation responsible for the release of lactate dehydrogenase (LDH), ferritin, C-reactive protein, D-dimers and interleukin into the systemic circulation [5, 6] . Indeed, the inflammatory state generated by this infectious process could activate the inflammatory cells constituting atherosclerotic plaques [7] .

Furthermore, signaling pathways related to angiotensin-converting enzyme 2 (ACE2) receptors may also play a role in the genesis of myocardial injury [8] . In fact, these receptors are the entry point of some coronaviruses such as SARS-CoV2 into human cells especially in the lungs and cardiovascular system where they are highly expressed [9] .

The epidemic context associated with Covid 19 makes the confirmation of the diagnosis of acute coronary syndromes, especially Non-ST-Elevation Myocardial Infarction (NSTEMI), more difficult in many cases because of the unreliability of troponin elevation, which can be elevated in many contexts, and the underutilization of coronary angiography given the infectious risk [8] . 

In the therapeutic management of patients admitted with acute coronary syndrome concomitant with SARS-CoV-2 infection, the risk of infection should be considered without delaying anti-ischemic management, according to many authors [11, 12] thrombolytic therapy was recommended in STEMI rather than primary PCI if Covid-19 was confirmed or could not be excluded quickly, whereas for NSTEMI, the priority was to exclude SARS-CoV-2 infection first.

These recommendations were endorsed by Daniels et al. According to this study, thrombolysis may be the best compromise for rapid patient reperfusion to gain time to treat and establish a complete diagnosis [13] .

Yet, according to several guidelines from the American College of Cardiology, the American College of Emergency Physicians (ACEP) and the American Heart Association [14, 15] primary angioplasty should remain the first choice and should be performed within an adequate time frame after the onset of symptoms, whenever possible, after an initial assessment in the emergency department of the risk of infection and thrombolytic therapy should not be the standard of care strategy and should be limited to specific situations.

In the same sense, the European and American general guidelines on STEMI [16, 17] , confirm that primary PCI remains the reperfusion treatment of choice if it is feasible within an acceptable time frame after the diagnosis of STEMI.

The platelet hyperactivity that accompanies COVID-19 infection shown in several studies, makes antiplatelet therapy very useful [18] , especially in ischemic heart disease like our case. In addition, the use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) does not have serious adverse effects in patients with COVID-19, as stated by the WHO [19] .

For thromboembolic risk assessment, it is recommended that the severity of COVID-19 be taken into consideration, based on the type of oxygen therapy required for the patient (none, nasal oxygen therapy, high-flow oxygen therapy, or mechanical ventilation) and the body mass index (BMI).

Some authors [20] propose to classify patients according to their thrombotic risk as follows:

-Low risk: non-hospitalized patients with a body mass index (BMI) < 30 kg/m², without associated risk factors. In cases of renal impairment (creatinine clearance < 30 ml/min), unfractionated heparin (UFH) is proposed at a dose of 200 IU/kg/24h for high risk and 500 IU/kg/24h for very high risk. It is also recommended that enoxaparin doses be adjusted for patients weighing > 120 kg and that anti-Xa activity be measured regularly [20] .According to some authors [20] , direct oral anticoagulants (DOAs) are a good alternative for patients without contraindications or drug interactions. For critical patients in the ICU setting with pulmonary embolism or DVT, LMWH or fondaparinux are preferred to DOAs. The period of anticoagulation should be three months. If there is a recurrence of thromboembolic events on DOAs, it is necessary to switch back to LMWH [20] .

The SCARE guildlines were used in the writing of this paper [21] .

SARS-CoV-2 infection has been associated with major cardiovascular complications, including acute myocardial infarction, myocarditis, heart failure, arrhythmia, and venous thromboembolic disease. In the absence of contraindication, thromboprohylaxis should be initiated for all hospitalized patients with COVID-19 to minimize the risk of thromboembolic complications.

The authors state that they have no conflicts of interest for this report Ethical Approval The ethical committee approval was not required give the article type case report. However, the written consent to publish the clinical data of the patients were given and is available to check by the handling editor if needed.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

A Novel Coronavirus from Patients with Pneumonia in China

Multiple cranial nerve palsies revealing blast crisis in patient with chronic myeloid leukemia in the accelerated phase under nilotinib during severe infection with SARS-COV-19 virus: Case report and review of literature

Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis

Brainstem stroke: A fatal thromboembolic event after new onset atrial fibrillation during covid-19 infection: A case report and literature review

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction

Syndromes and Covid-19: Exploring the Uncertainties

Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination

Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis

Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak

How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital

Elevation Myocardial Infarction in the COVID-19 Era: Business as Usual? Circulation

Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of

and the American College of Emergency Physicians (ACEP)

American Heart Association's Mission: Lifeline and Get With The Guidelines Coronary Artery Disease Advisory Work Group and the Council on Clinical Cardiology's Committees on Acute Cardiac Care and General Cardiology and Interventional Cardiovascular Care*. Temporary Emergency Guidance to STEMI Systems of Care During the COVID-19

AHA's Mission: Lifeline. Circulation

ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-Executive summary: A report of the American College of cardiology/American heart association task force on practice guidelines writing committee to revise the 199

Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19

The Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in Patients with COVID-19

The management of venous thromboembolism in hospitalized patients with COVID-19

for the SCARE GroupThe SCARE 2020 guideline: updating consensus surgical CAse REport (SCARE) guidelines

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement.The ethical committee approval was not required give the article type ( case report ) .However , the written consent to publish the clinical data of the patients was given and is available to check by the handling editor if needed J o u r n a l P r e -p r o o f Consent Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.Abdelaziz Boudihi : study concept or design, data collection, data analysis or interpretation, writing the paper Charmake Derare : data collection and management Mossab mazouzi : data collection Nabila ismaili : supervision and data validation Noha El ouafi : supervision and data validation J o u r n a l P r e -p r o o f

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study. This is not an original research project involving human participants in an interventional or an observational study but a case report . This registration is was not required

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish